Search clinical trials for: durvalumab placebo

Total 54365 results

AstraZeneca

Active, not recruiting

A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-1)

Hepatocellular Carcinoma

United States, Canada, France, Taiwan, Thailand, Vietnam, Italy, Korea, Republic of, Brazil, India, Japan, Mexico, Russian Federation, China, Hong Kong, Australia, Spain, Singapore
Alison Stopeck
Eli Lilly and Company; AstraZeneca

Withdrawn

Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer

Locally Advanced Breast Cancer | Hormone Receptor Positive Malignant Neoplasm of Breast | Breast Cancer Female

United States
Hebei Medical University Fourth Hospital

Recruiting

Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)

SCLC, Limited Stage

China
Dana-Farber Cancer Institute
AstraZeneca

Completed

A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)

Muscle Invasive Bladder Cancer

United States
Alexander Chi

Not yet recruiting

Combining ICI With SBRT or HypoFrx-RT for ES NSCLC

Non-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage II

China
Association NVALT Studies

Recruiting

Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC (NVALT28) (NVALT28)

Carcinoma, Non-Small-Cell Lung

Netherlands
Samsung Medical Center

Unknown

Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer

Esophageal Squamous Cell Carcinoma

Korea, Republic of
University Health Network, Toronto
AstraZeneca

Withdrawn

A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation (DOME)

Squamous Cell Carcinoma of Head and Neck | Non-small Cell Lung Cancer | Pancreatic Ductal Adenocarcinoma

Canada
Iovance Biotherapeutics, Inc.

Withdrawn

Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

United States
AstraZeneca

Recruiting

Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC (SAMETA)

Papillary Renal Cell Carcinoma

China, Czechia, Israel, Netherlands, Spain, United Kingdom, Korea, Republic of, Italy, India, Mexico, Turkey, Argentina, Australia, Canada, Germany, Russian Federation, Taiwan, United States, Poland, Brazil, Chile, Hong Kong, Ukraine, Franc... and more
NYU Langone Health
AstraZeneca

Withdrawn

Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer

Pancreatic Cancer

United States
Taofeek Owonikoko
AstraZeneca

Recruiting

Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC

Extensive-stage Small-cell Lung Cancer

United States
Peking Union Medical College Hospital

Recruiting

A Real-world Study of Durvalumab for Lung Cancer in China

Non Small Cell Lung Cancer Stage III | Small-Cell Lung Cancer

China
AstraZeneca

Completed

Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA) (CALLA)

Locally Advanced Cervical Cancer

United States, Taiwan, Korea, Republic of, Brazil, Hungary, India, Japan, Mexico, Peru, Philippines, Poland, Russian Federation, China, Chile, South Africa
MedImmune LLC

Completed

Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer

Head and Neck Cancer | Human Papilloma Virus

United States
Memorial Sloan Kettering Cancer Center
MedImmune LLC

Completed

Brain Irradiation and Tremelimumab in Metastatic Breast Cancer

Metastatic Breast Cancer

United States
Daniel George, MD
AstraZeneca

Withdrawn

TRIO Bladder: A Study of Durvalumab Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation in Muscle-Invasive Bladder Cancer (TRIO Bladder)

Bladder Cancer

United States
AstraZeneca

Active, not recruiting

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) (ORION)

Non-small Cell Lung Cancer NSCLC

United Kingdom, Belgium, United States, Korea, Republic of, Hungary, Japan, Russian Federation, Poland, Ukraine, India, Mexico, Netherlands
AstraZeneca

Recruiting

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin (VOLGA)

Muscle Invasive Bladder Cancer

Netherlands, United Kingdom, Korea, Republic of, Canada, Germany, Italy, Poland, Spain, Turkey, Vietnam, Argentina, Japan, France, Brazil, Taiwan, United States, Israel, Austria, Chile, Colombia, Greece, Hong Kong, Mexico, Portugal, Russian... and more
The University of Hong Kong

Recruiting

SBRT and Durvalumab for Inoperable/Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

Hong Kong
Mary Crowley Medical Research Center
AstraZeneca; Gradalis, Inc.

Completed

Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers

Cervical Cancer | Breast Cancer | Ovarian Cancer | Fallopian Tube Cancer | Endometrial Cancer | Primary Peritoneal Carcinoma | Uterine Cancer

United States
ARCAGY/ GINECO GROUP

Active, not recruiting

Tri Association in Patient With Advanced Epithelial Ovarian Cancer in Relapse (BOLD)

Epithelial Ovarian Cancer | Relapse

France
Ege University

Completed

Care to Caregiver: The Effect of Reflexology on Sleep and Anxiety of Cancer Caregiver

Sleep | Anxiety

Turkey
Institut für Klinische Krebsforschung IKF GmbH...

Recruiting

Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery

Esophagus Adenocarcinoma

Germany
Stanford University
AstraZeneca

Recruiting

Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

Non-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage II

United States
Washington University School of Medicine
AstraZeneca; Gateway for Cancer Research

Recruiting

Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer

Extensive-stage Small Cell Lung Cancer

United States
AUSL Romagna Rimini
AstraZeneca; Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori

Recruiting

Capecitabine Plus Concomitant Radiation Therapy Followed by Durvalumab as Preoperative Treatment in Rectal Cancer (PANDORA)

RECTAL CANCER

Italy
AstraZeneca

Recruiting

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer

Spain, United States, Belgium, United Kingdom, France, Hungary, Canada, Korea, Republic of, Australia
Dana-Farber Cancer Institute
AstraZeneca

Terminated

Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer

Recurrent Ovarian Carcinoma | Recurrent Cervical Carcinoma | Recurrent Endometrial Cancer | Metastatic Endometrial Cancer | Metastatic Cervical Cancer | Recurrent Vaginal Cancer | Recurrent Vulvar Cancer | Metastatic Ovarian Cancer | Recurrent Gynecological Cancer | Metastatic Vaginal Cancer | Metastatic...

United States
Ludwig Institute for Cancer Research
Boehringer Ingelheim; MedImmune LLC; PharmaJet, Inc.; CureVac; Cancer Research Institute...

Completed

Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC

NSCLC | Metastatic Non-small Cell Lung Cancer

United States
Novartis Pharmaceuticals

Completed

Phase ll Study of Imatinib Mesylate for the Neoadjuvant Treatment of Patients With Gastrointestinal Stromal Tumors (GIST) (CONVERT)

Gastrointestinal Stromal Tumors

Brazil
Beijing Chest Hospital

Not yet recruiting

Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLC

Extensive-stage Small-cell Lung Cancer
UConn Health
National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Institutes...

Completed

Pharmacogenetics of Alcohol: Treatment Implications

Alcoholism | Alcohol Related Disorders | Alcohol Abuse

United States
Jiping Wang, MD, PhD
AstraZeneca; Sirtex Medical

Recruiting

SIRT With Tremelimumab and Durvalumab for Resectable HCC

Hepatocellular Carcinoma | Hepatocellular Cancer | Resectable Hepatocellular Carcinoma

United States
Zhejiang Cancer Hospital

Not yet recruiting

Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung
Do-Youn Oh
AstraZeneca

Active, not recruiting

Neoadjuvant CCRT With Gemcitabine/Durvalumab (MEDI4736) Followed by Adjuvant Gemcitabine/Durvalumab(MEDI4736) in Resectable or Borderline Resectable Pancreatic Cancer

Pancreatic Cancer

Korea, Republic of
Jonsson Comprehensive Cancer Center
Bayer

Completed

Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer

Localized Resectable Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma

United States
Yale University

Completed

Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer

Breast Neoplasms

United States
hassan harby mohamed

Completed

Percutaneous Ethanol Injection for Benign Cystic Thyroid Nodules

Thyroid Nodule

Egypt
AstraZeneca

Active, not recruiting

Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC (NIAGARA)

Muscle Invasive Bladder Cancer

United States, Belgium, France, Germany, Italy, Spain, United Kingdom, Canada, Poland, Taiwan, Vietnam, Turkey, Korea, Republic of, Brazil, Czechia, Japan, Philippines, Israel, Chile, Australia, Netherlands, Russian Federation
Catherine Shu

Completed

SGI-110 Plus Durvalumab/Tremelimumab in SCLC

Extensive-stage Small Cell Lung Cancer

United States
Assistance Publique - Hôpitaux de Paris
Iltoo Pharma

Completed

Low Dose IL-2 Therapy in Patients With a Depressive Episode in the Course of a Bipolar Disorder (DEPIL-2)

Bipolar Depression

France
Orphan Australia

Completed

VSL#3 Versus Placebo in Maintenance of Remission in Crohn's Disease

Crohn's Disease

Australia
AstraZeneca

Active, not recruiting

Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) (MYSTIC)

Non-Small-Cell Lung Carcinoma NSCLC

United States, Belgium, Spain, Canada, Taiwan, Thailand, Vietnam, France, Germany, Italy, Korea, Republic of, Hungary, Japan, Russian Federation, Netherlands, Australia, Switzerland
AstraZeneca

Active, not recruiting

Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC (KUNLUN)

Esophageal Squamous Cell Carcinoma

Belgium, France, Spain, United States, Thailand, Vietnam, Brazil, Japan, Mexico, Russian Federation, Turkey, China, Taiwan, Canada, Korea, Republic of, Poland
Washington University School of Medicine

Completed

Alirocumab and Reverse Cholesterol Transport

Atherosclerosis | Coronary Heart Disease

United States
AstraZeneca
Daiichi Sankyo

Recruiting

Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung04)

Advanced or Metastatic NSCLC

United States, Taiwan, Italy, Spain, Poland, Japan, Belgium, Turkey, France, Korea, Republic of
Celgene

Completed

An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

Canada, Spain, United Kingdom, United States, France, Austria, Germany, Italy, Netherlands, Belgium, Portugal, Poland
MedImmune LLC

Completed

A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer (D4190C00006)

NSCLC | Lung Cancer | Non-small Cell Lung Cancer

United States, France, Italy, Spain, Belgium, United Kingdom, Korea, Republic of, Australia, Taiwan
National Cancer Institute (NCI)

Recruiting

Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma

Hepatocellular Carcinoma | Hepatocellular Cancer | Metastatic Hepatocellular Carcinoma

United States

Search clinical trials for: durvalumab placebo

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations